A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

Exclusion criteria

• . Pregnant or lactating
• . Has a significant clinical history, physical finding on clinical examination during screening, or presence of a disease that is active or requires treatment to control it, including cardiac, respiratory, endocrine, metabolic, autoimmune, liver, neurological, oncological, psychiatric, immunosuppresive/immunodeficient or other disorders which in the opinion of the investigator is not compatible with healthy status, may compromise the volunteer's safety, preclude vaccination or compromise interpretation of the immune response to vaccine. Individuals with mild/moderate, well-controlled comorbidities are allowed.
• . HIV 1 or 2 infection or indeterminate test at screening
• . History of anaphylaxis or angioedema
• . History of severe or multiple allergies to drugs or pharmaceutical agents
• . Known hypersensitivity to any component of the vaccine formulation used in this trial
• . History of severe local or general reaction to vaccination defined as
• . local: extensive, indurated redness and swelling involving most of the arm, not resolving within 72 hours